CYP2D6 genotype and tamoxifen activity: Understanding interstudy variability in methodological quality

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 2, 2013, Pages 185-187

  Ratain, M J ^a,b   Nakamura, Y ^a,b   Cox, N J ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b University of Chicago   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DIPHENHYDRAMINE; ENDOXIFEN; TAMOXIFEN;

BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESEARCH; CHROMOSOME ABERRATION; CLINICAL LABORATORY; COPY NUMBER VARIATION; DRUG EFFICACY; DRUG EXPOSURE; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GERMANY; HETEROZYGOTE; HUMAN; MOLECULAR EPIDEMIOLOGY; PHARMACOGENOMICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PSEUDOGENE; REPLICATION STUDY; RETROSPECTIVE STUDY; REVIEW; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; TAMOXIFEN;

EID: 84880758064     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.66     Document Type: Review

References (10)

1. Schroth, W. et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302, 1429-1436 (2009).
2. Brauch, H. et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J. Clin. Oncol. 31, 176-180 (2013).
3. Irvin, W.J., Jr et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J. Clin. Oncol. 29, 3232-3239 (2011).
4. de Graan, A.J. et al. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J. Clin. Oncol. 29, 3240-3246 (2011).
5. Madlensky, L. et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin. Pharmacol. Ther. 89, 718-725 (2011).
6. Abraham, J.E. et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res. 12, R64 (2010).
7. Schroth, W. et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin. Cancer Res. 16, 4468-4477 (2010).
8. Lyon, E. et al. Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. Genet. Med. 14, 990-1000 (2012).
9. Kiyotani, K. et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet. Genomics 20, 565-568 (2010).
10. Lorizio, W. et al. Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. Genome Med. 3, 64 (2011).